Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: study protocol for a multicenter randomized phase II trial (the OCUU-CRPC study)

BACKGROUND: Enzalutamide is an oral androgen receptor targeted agent that has been shown to improve survival in PREVAIL trials and has been approved for patients with chemo-naïve metastatic castration-resistant prostate cancer (CRPC). Meanwhile, flutamide is a non-steroidal oral anti-androgen that w...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Cancer
Main Authors: Iguchi, Taro, Tamada, Satoshi, Kato, Minoru, Yasuda, Sayaka, Yamasaki, Takeshi, Nakatani, Tatsuya
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2019
Assuntos:
Study Protocol
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6458677/
https://ncbi.nlm.nih.gov/pubmed/30971225
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-019-5526-3
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados